


# Evolution of the Global Biosimilars Market

## Global Market Access Insights

**Evolution of the Global Biosimilars Market** assesses the use and impact of biosimilar entrants across markets so you can identify opportunities for your product as the market evolves.

**Evolution of the Global Biosimilars Market** answers your questions so you can identify opportunities and risks for your brand.

- Implications for the U.S. market from experience in Europe
- Payer attitudes to access and defense tactics employed by manufacturers
- Best practice implications for market access by originator and biosimilar entrants










### You can use Evolution of the Global Biosimilars Market to:

- Assess** the different experiences between EU and American markets of biosimilar uptake
- Define** and predict market share and price erosion in target markets with successive biosimilar entrants
- Anticipate** the impact of upcoming biosimilar launches in the U.S. market
- Define** solutions for innovator and biosimilar products

<p><b>March 2019</b> Global Biosimilars Risk and Opportunities: Focus on European Union and United States</p>	<ul style="list-style-type: none"> <li>▪ What are the regulatory, legal and market access challenges for biosimilar entrants in the UK, France and Germany versus the U.S.?</li> <li>▪ What can be learned from the difference in biosimilar uptake and experience between countries?</li> <li>▪ How have biosimilars affected market volume, share and price by subsequent entrant and has this changed with experience?</li> <li>▪ What could this imply for the future U.S. market?</li> </ul>
<p><b>September 2019</b> Payer Perceptions of Biosimilar Competitive Dynamics</p>	<ul style="list-style-type: none"> <li>▪ What are the access tactics of biosimilar manufacturers across markets?</li> <li>▪ How are the access tactics perceived by payers across countries?</li> <li>▪ What are the perceptions of payers in different countries regarding the defense tactics of originator manufacturers?</li> <li>▪ Payer attitudes to biosimilar and originator manufacturers in the USA, UK and Germany</li> <li>▪ Best practice implications for market access of originator and biosimilar entrants in different markets.</li> </ul>
<p><b>October 2019</b> The Future Biosimilar Marketplace: Implications for Competitors in Next Generation Biosimilars</p>	<ul style="list-style-type: none"> <li>▪ What will the biosimilar marketplace look like in 2023? How will this differ from the current situation?</li> <li>▪ What are the trends that are likely to impact the evolution of the market?</li> <li>▪ How do payers expect to adapt to new biosimilar entries? How will their priorities change and what does this imply for manufacturers?</li> <li>▪ What are the major obstacles and threats to the biosimilar market that payers anticipate for the next 5 years?</li> </ul>

**Clients receive:**

 On-call access to our subject matter experts for your inquiries	 Access to our client portal, customized for your organization
 Client-exclusive webinar	 Unlocked PowerPoint slides
 On-site and virtual presentations with research leaders	 Access to source data
 Opportunity for input into research topics covered within the service	

Health Strategies Insights by EVERSANA reserves the right to change the timing and/or topics of its syndicated research publications.